МИЕЛОДИСПЛАСТИЧЕСКИЙ СИНДРОМ И ХЕЛАТОРНАЯ ТЕРАПИЯ
- Авторы: Грицаев С.В.1, Зотова И.И.1, Кострома И.И.1, Карпова Н.С.1, Абдулкадыров К.М.1
-
Учреждения:
- ФГУ Российский научно-исследовательский институт гематологии и трансфузиологии Федерального медико-биологического агентства, Санкт-Петербург
- Выпуск: № 17 (2011)
- Страницы: 48-52
- Раздел: Статьи
- URL: https://journals.eco-vector.com/2073-4034/article/view/279051
- ID: 279051
Цитировать
Полный текст
Аннотация
Ключевые слова
Об авторах
Сергей Васильевич Грицаев
ФГУ Российский научно-исследовательский институт гематологии и трансфузиологии Федерального медико-биологического агентства, Санкт-ПетербургФГУ Российский научно-исследовательский институт гематологии и трансфузиологии Федерального медико-биологического агентства, Санкт-Петербург
Ирина Ивановна Зотова
ФГУ Российский научно-исследовательский институт гематологии и трансфузиологии Федерального медико-биологического агентства, Санкт-ПетербургФГУ Российский научно-исследовательский институт гематологии и трансфузиологии Федерального медико-биологического агентства, Санкт-Петербург
Иван Иванович Кострома
ФГУ Российский научно-исследовательский институт гематологии и трансфузиологии Федерального медико-биологического агентства, Санкт-ПетербургФГУ Российский научно-исследовательский институт гематологии и трансфузиологии Федерального медико-биологического агентства, Санкт-Петербург
Наталья Сергеевна Карпова
ФГУ Российский научно-исследовательский институт гематологии и трансфузиологии Федерального медико-биологического агентства, Санкт-ПетербургФГУ Российский научно-исследовательский институт гематологии и трансфузиологии Федерального медико-биологического агентства, Санкт-Петербург
Кудрат Мугутдинович Абдулкадыров
ФГУ Российский научно-исследовательский институт гематологии и трансфузиологии Федерального медико-биологического агентства, Санкт-ПетербургФГУ Российский научно-исследовательский институт гематологии и трансфузиологии Федерального медико-биологического агентства, Санкт-Петербург
Список литературы
- Абдулкадыров К.М. Гематология. Новейший справочник по гематологии. М.: Эксмо; СПб. Сова. 2005. 928 с.
- Garcia-Manero G. Myelodysplastic syndromes: 2011 update on diagnosis, risk stratification, and management. Am J Hematol 2011;86:491-99.
- Greenberg PL. Current therapeutic approaches for patients with myelodysplastic syndromes. Br J Haematol 2010;150:131-43.
- Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs.
- Blood 2008;112:45-52.
- Sekeres MA. The epidemiology of myelodysplastic syndromes. Hematol Oncol Clin N Am 2010;24:287-94.
- Ma X, Does M, Raza A, Mayne ST. Myelodysplastic syndromes. Incidence and survival in the United States. Cancer 2007;109:1536-42.
- Oliva EN, Dimitrov BD, Benedetto F, et al. Hemoglobin level threshold for cardiac remodeling and quality of life in myelodysplastic syndrome. Leuk Res 2005;29:1217-19.
- Goldberg SL. Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes. Leuk Res 2007;31(Suppl. 3):16-22.
- List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005;352:549-57.
- List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006;355:1456-65.
- Hellstrom-Lindberg E, Willman C, Barrett AJ, Saunthararajah Y. Achievements in understanding and treatment of myelodysplastic syndromes. Hematology (Am Soc Hematol Educ Program) 2000:110-32.
- Lee NR, Park JH, Rhee KS. Acquired long QT syndrome and sudden cardiac death due to secondary hemochromatosis with multitransfusions for severe aplastic anemia. Ann Hematol 2008;87:933-35
- Porter JB. Concepts and goals in the management of transfusional iron overload. Am J Hematol 2007;82(Suppl. 1):1136-9.
- Gattermann N, Rachmilewitz EA. Iron overload in MDS - pathophysiology, diagnosis, and complications. Ann Hematol 2011;90:1-10.
- Messa E, Cilloni D, Saglio G. Iron chelation therapy in myelodysplastic syndromes. Adv Hematol 2010;2010:756289.
- Knovitch MA, Storey JA, Coffman LG, et al. Ferritin for the clinician. Blood Rev 2009;23:95-104.
- Malcovati L, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005;23:7594-603.
- Tucci A, Matta G, Deplane S, et al. Myocardial iron overload assessment by T2 magnetic resonance imaging in adult transfusion dependent patients with acquired anemias. Haematologica 2008;93:1385-88
- Konen E, Ghoti H, Goitein O, et al. No evidence for myocardial iron overload in multitransfused patients with myelodysplastic syndrome using cardiac magnetic resonance T2 technique. Am J Hematol 2007;82:1013-16
- Chacko J, Pennell DJ, Tanner MA, et al. Myocardial iron loading by magnetic resonance imaging T2 in good prognostic myelodysplastic syndrome patients on long-term blood transfusions. Br J Haematol 2007;138:587-93.
- Wood JC, Tyszka JM, Carson S, et al. Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. Blood 2004;103:1934-36
- Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88.
- Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007;25:3503-10.
- Garcia-Manero G, Shan J, Faderl S, et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia 2008;22:538-43.
- Sapena R, Vassilieff D, et al. Correlation between serum ferritin level at diagnosis and survival in lower risk, non-transfusion dependent, MDS patients. A report by the Groupe Francophone Des Myelodysplasies. Blood 2010;116:àbstr. 2916.
- Rose C, Brechignac S, Vassilief D, et al. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM. Leuk Res 2010;34:864-70.
- List AF, Baer MR, Steensma D, et al. Iron chelation with deferasirox (Exjade) improves iron burden in patients with myelodysplastic syndromes. Blood 2008;112:àbstr. 634.
- Greenberg PL, Koller CA, Cabantchik ZI, et al. Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes. Leuk Res 2010;34:1560-66
- Gattermann N, Finelli C, Porta MD, et al. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. Leuk Res 2010;34:1143-50.
- Ghoti H, Fibach E, Merkel D, et al. Changes in parameters of oxidative stress and free iron biomarkers during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndromes. Haematologica 2010;95:1433-35
- Wood JC, Kang BP, Thompson A, et al. The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. Blood 2010;116:537-43.
- Pennell DJ, Porter JB, Cappellini MD, et al. Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Blood 2010;115:2364-71.
- Cohen AR, Glimm E, Porter JB. Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major. Blood 2008;111:583-87
- Breccia M, Loglisci G, Salaroli A, et al. Deferasirox treatment interruption in a transfusion-requiring myelodysplastic patient led to loss of erythroid response. Acta Haematol 2010;124:46-8.
- Messa E, Carturan S, Maffe C, et al. Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging. Haematologica 2010;95:1308-16.
- Sanz G, Nomdedeu B, Such E, et al. Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome. Blood 2008;112:àbstr. 640.
- Leitch HA. Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy. Leuk Res 2007;31(Suppl. 3):7-9
- <http://www.ncbi.nlm.nih.gov/pubmed/18037416>